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Objective: To evaluate the feasibility, safety and accuracy of dobutamine/atropine stress echocardiography (DASE) for the 
detection of coronary artery disease (CAD) in renal transplant candidates.
Methods: Patients candidates to renal transplant were submitted consecutively to DASE and coronary angiography. The 
DGRSWHGDQJLRJUDSKLFFULWHULDIRU&$'ZHUHDQREVWUXFWLYHOHVLRQRIDQG
Results: 148 patients underwent the DASE and the coronary angiography. Mean age was 52 ± 9 years, and 69% of the patients 
were males; 27% had diabetic nephropathy and 73% had LVH; 63% were asymptomatic; 36% and 22% presented coronary 
REVWUXFWLRQVDQGUHVSHFWLYHO\7KH'$6(SHUIRUPDQFHZDVDQGPDMRUFRPSOLFDWLRQUDWHZDV7KH
sensibility, specificity and accuracy for the diagnosis of coronary obstruction > 50% were 53% (CI:45-61), 87% (CI:81-93), and 
75% (CI:63-83) respectively. For coronary obstruction > 70% these values were, respectively, 71% (CI:64-92), 85% (CI:79-
91) and 81% (CI:75-87). The sensibility to detect univessel and multivessel disease was 41% (CI:19-63) and 78% (CI:64-92), 
respectively.
Conclusion: The DASE was practical and safe; however, it presented a poor result for the detection of CAD regarding 
obstructions > 50%. It can be a useful screening for the detection of CAD in candidates with obstructions > 70% and 
multivessel disease.
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Renal transplant is increasingly becoming the ideal 
therapy for patients with chronic renal failure undergoing 
dialysis. As a consequence, there has been an increase in the 
number of receptors, which is disproportional to number of 
donated organs, resulting in the need for rigorous receptor’s 
selection criteria. 
In the last decades, with the great advances in 
immunosuppressive therapy and the introduction of more 
potent antibiotic drugs for infection control after the renal 
transplant, coronary artery disease (CAD) became one of the 
main causes of death in this population. Considering that, the 
researchers have emphasized the pre-existence of DAC as one 
of the most important factors associated to coronary events 
after renal transplant1. Moreover, prophylactic myocardial 
revascularization in renal transplant candidates has determined 
a longer survival when compared to the group undergoing 
clinical treatment alone2.
The clinical identification of CAD in this population, as 
well as its early detection through non-invasive techniques, 
presents practical difficulties in addition to the usual ones. 
These methods have shown to be insufficient regarding their 
diagnostic performance for surveillance, and therefore, some 
institutions prefer to use a systematic invasive investigation, 
although approximately two-thirds of these patients present 
unobstructed coronary arteries or with just non-significant 
lesions3. The ergometric analysis presents some limitations 
that hinder its use, such as: the degree of physical incapacity 
that prevents them from exercising normally4, the elevated 
prevalence of alterations in the ST5 segment at rest and the 
marked presence of LVH6. There is much controversy regarding 
the diagnosis sensitivity of the scintigraphy associated to 
dipiridamol in renal transplant candidates; Marwick et al7
found a sensitivity of 37%, whereas Boudreau et al8, found a 
sensitivity of 86%.
The dobutamine/atropine stress echocardiography (DASE) is 
a feasible and safe method in non-selected patients. However, 
despite the accumulated experience in this population, the 
method has not been sufficiently evaluated regarding these 
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aspects in patients with chronic renal failure (CRF). The DASE 
is an accurate method to detect CAD, locating and estimating 
with precision the disease extension9, but there have been few 
studies in renal transplant candidates.
Methods
From 2000 to 2003, patients that were renal transplant 
candidates, followed at the Renal Transplant Unit, were referred 
to evaluation at the Laboratory of Echocardiography and the 
Laboratory of Hemodynamics of the same Institution. The 
echocardiogram images were obtained from an ATL equipment, 
model Ultramark 9 HDI and the coronary angiographies were 
performed in a Phillips equipment. The examinations were 
carried out one day after the hemodialysis session. The inclusion 
criteria included the following: diabetic nephropathy or other 
causes of CRF and age older than 40 yrs, who presented 2 or more 
risk factors for DAC. Exclusion criteria included: previous history 
of myocardial infarction or surgical or percutaneous myocardial 
revascularization; unstable angina; decompensated congestive 
heart failure (CHF); significant aortic stenosis; pulmonary 
hypertension; hypertrophic cardiomyopathy; non-controlled 
DUWHULDOK\SHUWHQVLRQV\VWROLFEORRGSUHVVXUH6%3PP+J
after 30 min at rest); non-controlled atrial fibrillation or complex 
ventricular cardiac arrhythmia (non-sustained ventricular 
tachycardia, frequent, polymorphic bigeminated ventricular 
extrasystoles); inadequate echocardiographic window; atropine 
use restrictions (glaucoma and obstructive uropathy); irregular 
dialysis regimen and lack of patent’s informed consent.
Venous access was attained through venipuncture with 
a JELCO catheter. A solution containing 230 ml of 0.9% 
saline solution, to which 20 ml of a solution with 250 mg 
of dobutamine was added, resulting in a concentration of 1 
mg of dobutamine per ml was used. Administration of the 
solution was carried out by a peripheral vein, through an 
infusion pump, with progressive doses of 5, 10, 20 , 30 and 
40 µg/kg/min, with an increment every 3 min. In cases when 
the final objective of the evaluation had not been reached, the 
atropine was added, simultaneously, after the third minute of 
the infusion of 40 µg/kg/min of dobutamine, at a dose of 0.25 
mg every minute, up to a total maximum cumulative dose of 
1 mg10. Alternatively, isometric hand-grip exercise was used 
to attain slight increases in cardiac frequency. 
Intravenous metroprolol at a dose of 5 mg, was used when 
one of the following  symptoms appeared: significant side 
effect, myocardial ischemia, or persistence of the dobutamine 
effects after the end of the protocol. 
The reasons for test interruption were: end of the 
dobutamine infusion protocol; attaining 85% of the maximum 
cardiac frequency (CF) for age (220-age); new reversible 
alterations of segmental contraction and limiting side effects 
(angina, supraventricular tachycardia or sustained ventricular 
tachycardia), complex ventricular extrasystoles, atrial 
fibrillation, significant symptomatic hypotension, systolic 
DUWHULDOSUHVVXUHPP+JRUGLDVWROLFDUWHULDOSUHVVXUH
PP+JDQGXQEHDUDEOHGLVFRPIRUW
The test was considered diagnostic when at least one of 
these aims was reached: 85% of the maximum CF for age and 
echocardiographic signs of myocardial ischemia. The test was 
considered non-diagnostic when at least one of these situations 
came up: inadequate images for the analysis (lack of definition 
of at least 2 myocardial segments); end of the protocol of 
dobutamine infusion without reaching the target CF  with no 
manifested signs of myocardial ischemia and premature test 
withdrawal due to limiting side effects without attaining one 
of the test aims. 
Major test complications included: death, sustained 
ventricular tachycardia, ventricular fibrillation, acute 
pulmonary edema and acute ischemic syndrome (acute 
myocardial infarction or unstable angina).
The images at each stage were recorded in VHS tapes for 
all patients. When the quadruple screen system was available, 
the standard rest images were digitized and placed side by 
side to the corresponding images after each dobutamine 
infusion stage.
The recorded images were later interpreted by two 
members of the Stress Echocardiography team who were 
blinded to the patients’ clinical data, as independent 
observers. The discordance was solved by consensus between 
the two observers. The interpretation of the DASE was carried 
out according to the following criteria: Normal result defined 
as uniform increase of systolic movement and thickening of 
the left ventricular wall and consequent reduction of its final 
systolic volume (global hyperdynamic response). Positive 
result for myocardial ischemia was defined as a new alteration 
of the reversible segmental contractility or worsening of a 
pre-existing segmental alteration, in 2 or more contiguous 
myocardial segments.
The echocardiographic measurements were carried out 
according to the criteria established by the American Society 
of Echocardiography11. The calculation of the LVM was carried 
out by the M-mode measurement, using the formula of 
Devereux et al12; the LVM was obtained by the correction of 
the mass by the body surface area. The coronary angiography 
was carried out at the Outpatient Clinic one day after the 
hemodialysis for those who were undergoing such treatment. 
The Judkins technique was employed and the contrast 
used was non-ionic with low osmolarity. The angiographic 
studies were interpreted by two hemodynamicists who were 
blinded to the patients’ clinical data and DASE findings. The 
interpretation was carried out by visual estimation, using the 
following criteria for the quantification of degree of stenosis: 
absence of obstruction or obstruction < 50% of a main 
HSLFDUGLF FRURQDU\ DUWHU\ OXPHQ REVWUXFWLRQ DQG
REVWUXFWLRQ7KHWLPHLQWHUYDOEHWZHHQWKH'$6(DQG
the coronary angiography was not longer than 2 months. The 
study protocol was reviewed and approved by the Medical 
Ethical Committee of the Institution. Sensitivity was defined as 
the number of true positive tests divided by the total number 
of patients with angiographic stenosis at two obstruction levels, 
DQG6SHFLILFLW\ZDVGHILQHGDVWKHQXPEHU
of true negative tests divided by the total number of patients 
with angiographic stenosis < 50% and < 70%.
The positive predictive value was defined as the number 
of true positive tests divided by the total number of positive 
stress echocardiograms. The negative predictive value was 
defined as the number of true negative tests divided by the 
total number of negative stress echocardiograms. Accuracy 
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was defined as the number of true positive and true negative 
tests divided by the total number of patients. 
The measurement bias was controlled through the “blind” 
interpretation of the test regarding the coronary angiography, 
which was considered the reference standard. The continuous 
variables were expressed by means and SD. To analyze the 
differences between continuous variables, student’s t test was 
employed. The Chi-square test or Fisher’s exact test were used 
to compare differences between ratios. Statistical significance 
was set at p < 0.05.
Results
During the study period, 170 patients were referred for 
evaluation. According to the selection criteria, 12 patients were 
excluded and 158 consecutive patients who were candidates 
to renal transplant underwent DASE. Of these, 6 patients 
underwent the renal transplant before undergoing the coronary 
angiography, and 4 patients gave up participating in the study 
after undergoing DASE, remaining in the waiting list for the 
transplant. The remaining 148 patients who underwent DASE 
and the coronary angiography comprised the study group. Mean 
age was 52 ± 9 yrs (ranging from 23 to 78 yrs) with 101 male 
patients (69%) and 47 female ones (31%). The causes of CRF 
established by clinical and anatomopathological criteria were: 
SAH in 59 patients (40%), diabetic nephropathy in 40 (27%), 
chronic glomerulonephritis in 16 (4%) and other causes in 33 
(22%). The mean time of dialysis was 40 ± 37 months (ranging 
from 1 to 216 months) with a median of 24 months. There were 
134 patients (91%) undergoing a regular hemodialysis regimen 
at different Nephrology Services and 14 (9%) undergoing 
continuous outpatient peritoneal dialysis. Of the total, 93 (63%) 
of the patients were asymptomatic, 17 (12%) had a history of 
typical angina pectoris, 21 (14%) referred at least one episode of 
angina during the dialysis sessions and 39 (27%) had manifested 
signs and symptoms of congestive heart failure (CHF) at some 
point during their clinical evolution. 
The prevalence of CAD was established by the coronary 
DQJLRJUDSK\FRQVLGHULQJWZRGHJUHHVRIREVWUXFWLRQ
DQGUHVSHFWLYHO\
The prevalence of typical angina pectoris, atypical angina 
and angina during the dialysis, in the absence of significant 
obstruction of the coronary artery (< 50% of the vessel 
lumen) was 29%.  Asymptomatic patients, but who presented 
VLJQLILFDQWREVWUXFWLRQRIWKHFRURQDU\DUWHU\RIWKH
vessel lumen) corresponded to 56% of the sample. 
The diastolic diameters of the left ventricle varied from 35 
mm to 73 mm, with a mean value of 51 ± 7 mm. The left 
ventricular mass index (LVMI) varied from 71g/m² to 349g/m², 
with a mean value of 182 ± 61g/m². The ejection fraction 
(EF) of the left ventricle varied from 23% to 84%, with a mean 
value of 67 ±12%; 108 patients (73%) presented left ventricle 
hypertrophy (LVH). Diastolic dysfunction of the LV was present 
in 24 patients (16%). The duration of DASE was on average 12 
± 3 minutes (2-19 min) and the mean dose of dobutamine 
infused during the examinations was 36  ± 7 µg/Kg/min (10µg/
kg/min to 40µg/kg/min). Of the total number of examinations, 
22 patients (18%) needed atropine to attain submaximum 
cardiac frequency or to conclude the protocol and 17 (14%) 
were submitted to the isometric hand grip when the maximum 
dose of dobutamine had been reached and there were only a 
few heart beats left to reach the target CF. 
The hemodynamic test data are shown in Table 1.
REST PEAK p
CF 78 + 11 139 + 19 < 0.05
DBP 92 + 12 81 + 20 < 0.05
SBP 155 + 22 165 + 44 0.222
DP 12,192 + 2,685 22,549 + 5,168 < 0.05
CF= cardiac frequency; DBP= diastolic blood pressure; SBP= systolic 
blood pressure; DP (CF x SBP) = double product
Table 1 - Hemodynamic data of DASE in patients with CRF being 
evaluated for renal transplant. 
Of 148 patients submitted to the test, 135 finished the 
protocol, which corresponds to a feasibility of 91%. The 
reasons that led to test interruption were: attaining 85% of 
maximum CF for age: 121 (81%); limiting side effects: 13 
(9%); echocardiographic signs of ischemia: 10 (7%) and end 
of the protocol: 4 (3%).
Thirteen patients presented an early withdrawal of the 
protocol due to limiting side effects: 12 (8.5%) due to 
hypertensive response and 1 (0.5%) due to severe angina. Most 
of these situations were promptly reverted with test withdrawal 
and 5 patients needed metropolol administration. Mean systolic 
arterial pressure at rest was significantly higher in the group that 
developed a hypertensive response (170±26mmHg) than in 
the group that did not (152±27), p=0.009. 
 The complications observed during DASE are shown in 
Table 2.
Major complications Number Percentage (%)
Death, AMI, UA and Acute 
Pulmonary Edema 0 0
Prolonged angina 1 0.7
Complex ventricular 
Arrhythmia (NSVT) 3 2
Total 4 2.7
Minor complications
Significant SAH 12 8.5
Marked hypotension 11 8
V or SV extra-systole 22 15
Atrial fibrillation 1 0.7
Headache, nausea, 
palpitation, tremors 16 12
Total 62 44
SAH=systemic arterial hypertension; AMI=acute myocardial 
infarction; V=ventricular; SV=supraventricular; UA= Unstable Angina; 
NSVT=non-sustained ventricular tachycardia.
Table 2 - Complications observed during DASE in renal 
transplant candidates 
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The DASE induced arterial hypotension in 38 patients (27%); 
of these, 11 patients (8%) developed a more accentuated degree 
RIDUWHULDOK\SRWHQVLRQ6%3GHFUHDVHPPKJ1RQHRI
these patients had to be prematurely withdrawn from the study 
due to the arterial hypotension. Neither the extension nor the 
severity of the lesion were associated to the hypotension: P= 
0.458 and CAD > 70%: p=0.667. Groups with and without 
LV dysfunction presented similar results (p=0.180).
One hundred and twenty-six tests (85%) were considered 
diagnostic. In 22 patients (15%), the test was not considered 
diagnostic due to the following reasons: 5 (4%) due to 
inadequate image (considered by at least 1 observer); 13 
(10%) due to limiting side effects and 4 (3%) for not attaining 
the target cardiac frequency at the end of the protocol without 
presenting echocardiographic signs of myocardial ischemia. 
The results of the DASE regarding the presence or absence 
RI&$'RULQWKHSDWLHQWVZLWKFRQFOXVLYH
diagnostic tests are shown in Tables 3 and 4.
Table 5 shows the diagnostic DASE indexes, with their 
respective confidence intervals, for both degrees of coronary 
obstruction considered in the study.
The correlation between DASE results and the severity 
of CAD was analyzed. The data shown as mean values are 
depicted in Table 6. 
Discussion
The present study evaluated the dynamic response, 
feasibility, safety and performance of DASE in the largest cohort 
available in the current Literature to date, of patients who 
were candidates to renal transplant, systematically submitted 
to coronary angiography. 
When comparing the data of the present study with other 
DASE series carried out in the general population, we observe 
a similarity regarding the test feasibility. The percentage of non-
diagnostic tests due to the inadequate acoustic window was, 
on the whole, 5% in the general series13,14, which corresponds 
to the value of 4% of this study. Tests considered as non-
diagnostic occurred in 10% in the series by Poldermans et al14
and Picano et al15, close to the 13% of cases in the present 
series. Regarding particularly the studies that analyzed DASE 
in patients with pre-renal transplant CRF, only Reis et al16
defined data regarding the feasibility. These authors obtained 
80% of diagnostic tests.
The non-cardiac side effects observed in this study 
occurred at a frequency that was similar to those described 
by Mathias et al17 in an extensive series of 4,033 non-chronic 
renal failure patients. However, they were slightly higher 
than those observed by Secknus et al18, in 3,011 general 
population patients. Among the studies performed in patients 
CAD>50%n (%) CAD< 50% n (%) Total
DASE (+) 26(20%) 10(8%) 36(29%)
DASE (-) 23(18%) 67(54%) 90(71%)
Total 49(38%) 77(62%) 126(100%)
DASE= dobutamine/atropine stress echocardiography. 
Table 3 - DASE results considering coronary artery obstructions >
50%, in renal transplant candidates.
&$'Q CAD< 70% n (%) Total
DASE (+) 24(19%) 14(11%) 38(30%)
DASE (-) 10(8%) 78(62%) 88(70)%
Total 34(27%) 92(73%) 126(100%)
DASE= dobutamine/atropine stress echocardiography. 
Table 4 - DASE results considering coronary artery obstructions >
70%, in renal transplant candidates.
Obstruction Se (%) Sp (%) PPV (%) NPV(%) Accuracy
 53 (45-61)* 87 (81-93) 72 (65-81) 74 (67-82)* 74 (63-83)
 71 (63-79)* 85 (79-91) 63 (56-72) 89 (83-95)* 81 (75-87)
( ) = 95% Confidence Interval; Se = sensitivity; Sp = specificity; PPV = positive predictive value; NPV = negative predictive value; A= accuracy
* p<0.05
Table 5 - Sensitivity , specificity , positive predictive value, negative predictive value, and accuracy of DASE for the diagnosis of CAD in patients 
with CRF, at both levels of coronary obstruction  (> 50% and > 70%).
S(%) E(%) VPP (%) VPN(%) A(%)
UNI 41(19-63)* 72(52-92) 33(12-54) 81(63-99) 64(42-86)#
MULTI 78(64-92)* 76(62-90) 31(16-46) 96( 90-99)* 76(61-89)#
Se = sensitivity; Sp = specificity; PPV = positive predictive value; NPV = negative predictive value; A= accuracy; UNI = univessel; MULTI = 
multivessel. * p= 0.032; # p=0.05
Table 6 - Sensitivity, specificity, Positive predictive value, negative predictive value, and accuracy of DASE for the 
diagnosis of univessel and multivessel CAD in renal transplant candidates (coronary obstruction >50%).
44
Original Article
Ferreira et al
FEASIBILITY, SAFETY AND ACCURACY OF DOBUTAMINE/ATROPINE STRESS ECHOCARDIOGRAPHY
FOR THE DETECTION OF CORONARY ARTERY DISEASE IN RENAL TRANSPLANT CANDIDATES
Arq Bras Cardiol 2007; 88(1) : 41-47
with pre-transplant CRF, Bates et al19 found elevated side 
effect rates (36%).
The systemic arterial hypotension observed in studies with 
DASE in the general population has varied from 5% to 37%20,21.
In the present series, we found a prevalence of 27% of arterial 
hypotension, with 8% being the most severe form, a situation 
that did not cause test withdrawal. Reis et al16, evaluating CRF 
patients, reported 26% of arterial hypotension prevalence, 
which was not a cause for DASE interruption, either.
The hypertensive response was the most important cause 
of DASE interruption in the present study (8.5%), which a 
higher rate than those seen in series involving the general 
population (1%)18,17. In the studies carried out in patients with 
CRF, this complication caused the interruption of the test in 
2% to 6% of the cases16,19,22. In the present study, this fact can 
be attributed to the elevated mean of the systemic arterial 
pressure at rest.
Previous DASE studies23,14, carried out in the general 
population, reported similar rates of ventricular or 
supraventricular extra-systoles, similar to those detected in 
the present study. Higher frequencies of ventricular extra-
systoles were reported by Mathias et al17. The present series 
showed only 1 case of atrial fibrillation (0.7%), similar to that 
reported by Mathias et al17, but 3-fold lower than the series 
by Herzog et al22, who studied patients with CRF.
Therefore, the presence of CRF was not a difficulty factor for 
performing DASE, and was not an additional risk factor to this 
kind of patient, except for the marked hypertensive response, 
which could have been prevented with better ambulatory 
control of hypertension. 
In this series, the mean test duration was 12 ± 3 minutes 
and the mean dose of dobutamine infused at the test peak 
was 36 ± 7µg/kg/min. This dose was similar to those utilized 
in standard protocols in the general population24 and also in 
pre-transplant patients with CRF. 
In the present study, at the peak of the pharmacological 
infusion, the mean double product (DP) found was 22,549 ± 
5,168 mmHg/min. This value is higher than those reported by 
Rallids et al25, for the DASE (19,339 ± 3,923), as well as for 
the echocardiogram associated with physical stress (24,577 ± 
5,680). There were also similarities between the hemodynamic 
response found in this study when compared to other studies 
carried out in patients with CRF22,19.
In this study, the following sensitivity, specificity and 
accuracy means were obtained, considering a coronary 
REVWUXFWLRQDQG UHVSHFWLYHO\7KH
VDPHLQGH[HVFRQVLGHULQJDFRURQDU\VWHQRVLVZHUH
71%, 85% and 81%. Although a low sensitivity to diagnose 
univessel disease was observed (41%), the sensitivity for the 
diagnosis of patients with multivessel disease was considered 
good and was significantly higher (78%; P < 0.05) than that 
of the univessel disease. 
These results have been also observed in the population 
of patients with normal renal function25-28.
In a recent review de 28 DASE studies involving 2,246 
patients from the general population, mean sensitivity values of 
80% have been described9. However, this analysis has shown a 
broad sensitivity variation among the studies, varying from 40% 
to 97%. This ample variation might be related to the applied 
methodology, such as: percentage of male patients included; 
inclusion of patients with myocardial infarction; patients with 
high pre-test probability of CAD; number of patients with 
multivessel disease; specific analysis of patients with univessel 
disease; use of beta-blockers and use of different criteria of 
coronary obstruction. 
When comparing this study with others carried out in 
patients that were candidates to renal transplant, one can 
observe differences among them. Initially, three of the four 
studies had as the main objective to evaluate the prognostic 
value of DASE16,19,29. Regarding the sample size, no study 
reported a number > 100 patients, varying from 47 to 97 
cases, with a mean of 62 cases16,19,29,22. In the first series, 
the number of patients who underwent DASE and coronary 
angiography varied from 25%29 to 35%16,19. More recently, 
Herzog et al22 performed a coronary angiography in 50 
(100%) of the studied patients. The patients studied by those 
authors had a pre-test probability of CAD that was higher 
than this series. The prevalence of CAD varied from 54%22
to 77%16. The reference bias was well characterized in some 
studies16,19, as for these authors, the positive DASE was the 
most important indication for coronary angiography and only 
a small number of patients with normal DASE underwent the 
invasive procedure. 
As a consequence, the sensitivities in those studies, 
considering the 95% CI, presented a broad variation that 
ranged from 38% to 95%16,19,29,22. There was also a broad 
variation regarding specificity, as low as 14%19 and as good as 
86%16, differences that can be attributed to the methodology 
employed in each study.
Recently, de Lima et al30 evaluated the accuracy and the 
prognostic value of DASE and the scintigraphy, comparing the 
results with those by angiography in renal transplant candidates. 
The authors found low sensitivity of DASE (43%) in the detection 
RI&$'ZLWKREVWUXFWLRQLQSDWLHQWV
The extension of the area at risk can influence the accuracy 
of tests to evaluate ischemia. The present study showed a 
significant difference regarding DASE sensitivity in patients with 
multivessel disease when compared to those with univessel 
disease. These data are in accordance with several investigators 
who evaluated the performance of DASE, regarding this aspect, 
in the general population28, 31-33. Therefore, the predominance 
of univessel lesions, affecting 2/3 of patients with obstructions 
ZDVRQHRIWKHGHWHUPLQDQWVRIWKHWHVW·VORZVHQVLWLYLW\
in the studied group. 
Another factors associated to the DASE false-negative 
response was the degree of coronary obstruction < 70%. 
Patients with intermediary coronary stenosis (obstruction 
between 40% and 70%) frequently do not present a reduction 
in the coronary flow reserve34, and thus the sensitivity of 
ischemic tests can be compromised. In the present study, 78% 
of the patients had coronary artery disease with obstruction < 
70%, also contributing to the reduction in sensitivity.
The reduced prevalence of relevant coronary stenosis 
in the present study was due to the main study aim. The 
surveillance studies involve the use of a test in a predominantly 
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